• 1. Anticancer activity of pyrimidodiazepines based on 2-chloro-4-anilinoquinazoline: synthesis, DNA binding and molecular docking
  Viviana Cuartas,Alberto Aragón-Muriel,Yamil Liscano,Dorian Polo-Cerón,Maria del Pilar Crespo-Ortiz,Jairo Quiroga,Rodrigo Abonia,Braulio Insuasty RSC Adv. 2021 11 23310
• 2. 356. Synthetic antimalarials. Part XXXI. 2-p-chloroanilino-4-β-diethylaminoethylaminoquinazolines containing various substituents in the quinazoline nucleus
  F. H. S. Curd,J. K. Landquist,F. L. Rose J. Chem. Soc. 1948 1759
• 3. Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway
  Subramanyam J. Tantry,Vikas Shinde,Gayathri Balakrishnan,Shankar D. Markad,Amit K. Gupta,Jyothi Bhat,Ashwini Narayan,Anandkumar Raichurkar,Lalit Kumar Jena,Sreevalli Sharma,Naveen Kumar,Robert Nanduri,Sowmya Bharath,Jitendar Reddy,Vijender Panduga,K. R. Prabhakar,Karthikeyan Kandaswamy,Parvinder Kaur,Neela Dinesh,Supreeth Guptha,Ramanatha Saralaya,Manoranjan Panda,Suresh Rudrapatna,Meenakshi Mallya,Harvey Rubin,Takahiro Yano,Khisi Mdluili,Christopher B. Cooper,V. Balasubramanian,Vasan K. Sambandamurthy,Vasanthi Ramachandran,Radha Shandil,Stefan Kavanagh,Shridhar Narayanan,Pravin Iyer,Kakoli Mukherjee,Vinayak P. Hosagrahara,Suresh Solapure,Shahul Hameed P,Sudha Ravishankar Med. Chem. Commun. 2016 7 1022
• 4. Structure–activity relationship studies of SETD8 inhibitors
  Anqi Ma,Wenyu Yu,Yan Xiong,Kyle V. Butler,Peter J. Brown,Jian Jin Med. Chem. Commun. 2014 5 1892

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines
• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds

Recent Advances in the Research of 2,4-Dichloro-6,7-dimethoxyquinazoline (CAS: 27631-29-4)

2,4-Dichloro-6,7-dimethoxyquinazoline (CAS: 27631-29-4) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of kinase inhibitors. Recent studies have highlighted its significance in medicinal chemistry due to its versatile reactivity and potential applications in drug discovery. This research brief consolidates the latest findings on this compound, focusing on its synthesis, biological activity, and therapeutic potential.

A recent study published in the Journal of Medicinal Chemistry explored the use of 2,4-Dichloro-6,7-dimethoxyquinazoline as a precursor for the synthesis of novel EGFR (Epidermal Growth Factor Receptor) inhibitors. The study demonstrated that modifications at the 2 and 4 positions of the quinazoline ring significantly enhanced the inhibitory activity against mutant forms of EGFR, which are often implicated in non-small cell lung cancer (NSCLC). The researchers employed a combination of computational modeling and in vitro assays to optimize the compound's pharmacokinetic properties, resulting in a lead candidate with improved bioavailability and reduced off-target effects.

Another noteworthy development is the application of 2,4-Dichloro-6,7-dimethoxyquinazoline in the design of multi-targeted kinase inhibitors. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported the synthesis of a series of derivatives targeting both VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and PDGFR (Platelet-Derived Growth Factor Receptor). These derivatives exhibited potent anti-angiogenic effects in preclinical models, suggesting their potential for treating solid tumors and other angiogenesis-dependent diseases. The study also emphasized the compound's role in facilitating rapid structure-activity relationship (SAR) studies due to its high reactivity.

In addition to its therapeutic applications, recent advancements in synthetic methodologies have improved the scalability and yield of 2,4-Dichloro-6,7-dimethoxyquinazoline production. A team at the University of Cambridge developed a novel one-pot synthesis route using microwave-assisted techniques, reducing the reaction time from 12 hours to under 2 hours while maintaining a yield of over 85%. This innovation addresses previous challenges in large-scale production, making the compound more accessible for industrial applications.

Despite these promising developments, challenges remain in optimizing the selectivity and toxicity profiles of derivatives derived from 2,4-Dichloro-6,7-dimethoxyquinazoline. Future research directions may include the exploration of novel substitution patterns and the integration of proteolysis-targeting chimera (PROTAC) technology to enhance target specificity. Overall, the compound continues to be a valuable scaffold in drug discovery, with its potential yet to be fully realized.

• 13790-39-1(4-chloro-6,7-dimethoxy-quinazoline)
• 62484-30-4(Quinazoline, 2,4-dichloro-6-methoxy-7-(1-methylethoxy)-)
• 105763-77-7(2,4-Dichloro-6-methoxyquinazoline)
• 62484-31-5(2,4-Dichloro-7-methoxyquinazoline)
• 55496-52-1(4-Chloro-7-methoxyquinazoline)
• 62484-34-8(Quinazoline, 7-butoxy-2,4-dichloro-6-methoxy-)
• 62484-25-7(Quinazoline, 2,4-dichloro-6-methoxy-7-propoxy-)
• 574745-97-4(4-Chloro-7-methoxyquinazolin-6-ol)
• 62484-32-6(Quinazoline, 2,4-dichloro-7-ethoxy-6-methoxy-)
• 61948-59-2(2,4-Dichloro-5-methoxyquinazoline)